SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is generating considerable buzz around its potential acquisition of Warner Bros. Discovery, with speculation focusing on a revised all-cash offer amidst legal challenges from Paramount Skydance. This highly anticipated deal, alongside upcoming earnings, has polarized the community between those expecting a significant pre-earnings rally and others anticipating further volatility and potential downside, fueled by concerns over market manipulation and political opposition.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery (WBD) is trending as it navigates an escalating takeover battle, with its board reportedly favoring Netflix's acquisition proposal over Paramount Skydance's (PSKY) all-cash offer, despite a personal financing guarantee. The community is buzzing with debate, weighing PSKY's perceived superior value and the potential for a significantly higher bid from either contender to secure market dominance in the evolving media landscape. Shareholders are closely watching for definitive developments in this strategic consolidation.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending due to a significant sell-off, with community discussion centering on ongoing CEO stock sales and potential competitive impacts from new AI agents like Anthropic's Claude Cowork. Despite this, many investors view the sharp dip as a strong buying opportunity, banking on the company's solid fundamentals, evolving leadership in agentic automation, and strategic partnerships to drive future growth.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as the community reacts to positive developments concerning its pipeline, including global regulatory submissions for its seasonal flu vaccine and plans for a combined flu and COVID vaccine. Bulls are emphasizing the company's long-term potential in oncology and the possibility of a short squeeze, while others remain skeptical about its valuation and future revenue growth.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending amid a wave of analyst downgrades and intensified debate around increasing AI-driven competition, notably from Apple's new creative software suite. While many investors see the stock as deeply undervalued given strong fundamentals and ongoing share buybacks, others express deep concern that AI advancements will erode Adobe's long-term market dominance. The community is sharply divided between those who believe the current dip is a prime buying opportunity and those who view it as a signal of structural weakness for the software giant.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending amidst widespread community speculation about an imminent major partnership or acquisition, notably with Big Pharma firms, fueled by recent FDA flexibility regarding CMC requirements and upcoming industry conferences. Investors are keenly anticipating a substantial buyout and a potential short squeeze, given the promising Phase 3 data for its lead prostate cancer drug and upcoming Biologics License Application submission in 2026. This fervent discussion occurs within a broader market context of accelerated biopharma M&A activity driven by looming patent cliffs.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending due to an imminent shareholder vote on a massive proposed increase in authorized shares and executive compensation. Community perspectives are sharply divided, with significant retail investor frustration over perceived dilution and the stock's underperformance relative to Ethereum's recent strength. This crucial decision, alongside ongoing concerns about market manipulation and the company's strategy to expand its Ethereum treasury, is fueling widespread debate and anxiety among shareholders.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending due to its continued strategy of accumulating significant Bitcoin holdings, which has sparked renewed optimism among investors. Community discussions highlight strong bullish sentiment and the potential for a short squeeze, although some express concern about the impact of the company's equity offerings. Ultimately, many believe MSTR's performance remains highly correlated with Bitcoin's sustained upward trajectory.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

CockCardano ($COCK) is a vibrant Cardano-based meme coin trending due to its unique real-world asset (RWA) venture, CockyWings, which sells chicken wings. The enthusiastic 'Flock' community is actively engaged, highlighting the project's innovative staking features, consistent building, and strong potential within the broader Cardano ecosystem.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

Immediate market discussions center on the reported criminal probe into Fed Chair Powell, sparking intense debate over central bank independence and the potential for political influence on monetary policy. This uncertainty is compounded by recent U.S. action in Venezuela and proposed credit card interest rate caps, leading to polarized community views on heightened geopolitical risks and significant financial sector shifts. While the Dow Jones Industrial Average (DIA) has recently achieved new highs, its rally's sustainability is keenly debated amidst concerns over broader market fragility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

Novavax (NVAX) shares traded 1% higher in the pre-market session on Tuesday after its second-largest shareholder, Shah Capital, called for the sale of the company, citing persistent underperformance.Shah Capital currently owns 11.8 million shares or 7.2% of Novavax. The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.shahcapital.com/shah-capital-calls-for-sale-of-novavax/">said</a> in a letter to the Novavax board of directors that since March 2023, its concerns have accelerated with “Nuvoxovid’s rollout slipups including this fall, timid/ineffective marketing, extremely poor capital market actions, and tremendous lack of accountability.”“Novavax’s IP and scientific capabilities will have far greater upside potential in the hands of large capable pharma entity,” Shah Capital said, while recommending an immediate formal strategic review for the sale of the company.The investor recapped several alleged missteps that have damaged the company, including critical marketing slips resulting in a small 2% Covid vaccine market share in the 2024 season for Novavax’s protein-based Nuvaxovid vaccine.Shah Capital also expressed surprise at Nuvaxovid’s market share, noting that the increasing criticism for mRNA vaccines made by Novavax’s peers should benefit Novavax’s protein-based vaccine.“With more states becoming increasingly averse to mRNA vaccines including Florida, Texas, Minnesota, Idaho, Iowa, Montana, South Carolina, Tennessee &amp; Kentucky; some of which are trying to ban mRNA altogether, we find it inconceivable as to how management has been unsuccessful gaining meaningful share given the tens of millions of senior citizens/high risk/immunocompromised individuals in just those 9 states alone. Sales are miserable for the third consecutive year,” it said.The investor also noted that awareness regarding Nuvaxovid continues to be “alarmingly low.” Shah further alleged that the “execution failure and ineffective leadership” have taken their toll on investor confidence and trust.Last year, Shah Capital waged a proxy campaign against the re-election of some directors on the company board at Novavax’s 2024 Annual Meeting, but withdrew it after the company struck a licensing agreement with Sanofi.Sanofi is Novavax’s biggest partner. In the second quarter (Q2), the $199 million received from Sanofi accounted for over 83% of Novavax’s total revenue of $239 million.<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> is up by 7% this year but down by about 32% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-appoints-ceo-charlie-scharf-as-chairman-after-q3-earnings-beat-estimates/ch6mVM6R3mE">Wells Fargo Appoints CEO Charlie Scharf As Chairman After Q3 Earnings Beat Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.

Equity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.


Shares of MoonLake Immunotherapeutics (MLTX) rebounded 14% on Tuesday after a near 90% plunge on Monday.MoonLake on Sunday <a href="https://stocktwits.com/news-articles/markets/equity/moonlake-stock-crashes-premarket-after-sonelokimab-phase-3-data/chDMDY2R37p">announced</a> 16-week results from its late-stage VELA-1 and VELA-2 identical trials of Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS), also known as acne inversa — a chronic inflammatory condition characterized by painful, boil-like nodules that can rupture, drain pus, and leave scars.In VELA-1, Sonelokimab achieved statistical significance for all primary and key secondary endpoints, including a substantial improvement in the disease. However, in VELA-2, the drug failed to achieve statistical significance. Subsequently, on Monday, MLTX closed at $6.25, marking its lowest levels in over three years. The stock is currently trading at $7.41.The mixed data drew several price target cuts. Needham analyst Serge Belanger lowered the firm's price target on MoonLake Immunotherapeutics to $20 from $66 on Tuesday, but maintained a ‘Buy’ rating on the shares. The regulatory path looks uncertain, and MoonLake might need to conduct another late-stage trial in the worst-case scenario, the analyst noted.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_1_04_46_PM_png_2ebbe1ed61.webp" alt="MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rise further.<stembedurl>https://stocktwits.com/Leoheart/message/630505115</stembedurl>Another noted that, although analysts have cut price targets, several targets remain higher than current trading levels.<stembedurl>https://stocktwits.com/Freeballin02/message/630504990</stembedurl>Guggenheim also lowered the firm's price target on the stock to $20 from $80 and kept a ‘Buy’ rating on the shares. While investors are now focused on the drug’s regulatory path, the firm noted that MoonLake is conducting multiple clinical studies across other indications, including palmoplantar pustulosis, psoriatic arthritis, and axial spondyloarthritis. These together sum up to a multibillion-dollar market, the firm noted.Citi analyst Samantha Semenkow, meanwhile, downgraded MoonLake Immunotherapeutics to ‘Neutral’ from ‘Buy’ with a price target of $5, down from $72, on "significant" regulatory risk for the drug. The analyst also noted that Moonlake is currently facing financing challenges.MLTX stock is down by 89% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anaptysbio-stock-gets-price-target-hike-after-announcing-plan-to-separate-royalty-biopharma-business/chDDWF9R39Q">AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.

Capricor Therapeutics (CAPR) said on Thursday that it expects to submit fresh trial data to the U.S. Food and Drug Administration to get its Deramiocel therapy approved in the treatment of Duchenne muscular dystrophy.The FDA <a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-plunges-after-us-fda-declines-approval-for-muscular-disorder-therapy/ch8cfZ4R5Zn">stated</a> in July that it was unable to approve the application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness, and expressed the need for additional clinical data.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/326/capricor-therapeutics-provides-regulatory-update-on">stated</a> on Thursday that it held a meeting with the agency and hopes to submit data from its HOPE-3 late-stage clinical trial as part of its current application. Topline data from the trial, which will serve as the additional study requested by the agency, is expected in the fourth quarter.Shares of the company rose 5% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.“The FDA remains committed to collaborating with the applicant and will exercise further regulatory flexibility by reviewing data from the HOPE-3 trial,” the FDA said in a meeting with the company.“With HOPE-3 completed and data expected later this year, we remain confident in our ability to advance Deramiocel toward potential approval,” CEO Linda Marbán said.The company also stated that it maintains a “strong financial position” to support the advancement of Deramiocel through regulatory review and toward a potential launch for treating Duchenne Muscular Dystrophy (DMD).DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.CAPR stock is down by about 55% this year and by about 40% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bristol-myers-to-sell-plaque-psoriasis-drug-for-over-80-percent-discount-starting-2026/chDlId9R34B">Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Capricor Stock Rises Pre-Market Over Fresh Hopes Of Deramiocel Approval In Treating Genetic Disorder

The company announced on Thursday that it held a meeting with the agency and plans to submit data from its HOPE-3 clinical trial as part of its current application.

Shares of Trump Media &amp; Technology Group (DJT), the parent company of Truth Social, fell nearly 7% on Wednesday, after a series of high-profile stock sales by key executives, prompting bearish sentiment among retail investors.According to recent SEC filings, the company’s CFO, Phillip Juhan, sold $1.92 million worth of shares, while CEO Devin Nunes offloaded shares worth $63,210.&nbsp;Other executives who sold shares include COO Andrew Northwall ($78,700), CTO Vladimir Novachki ($177,082) and General Counsel and Secretary Scott Glabe ($92,684).The filings clarify that these sales were conducted to cover withholding payments to taxing authorities, with no cash proceeds received by the executives.&nbsp;However, the optics of top executives selling shares have rattled investors.On Stocktwits, sentiment for DJT has turned ‘extremely bearish’ (13/100) amid high levels of chatter.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DJT_sentiment_and_message_volume_Aug_28_c3c9ff623c.png" alt="DJT sentiment and message volume Aug 28.png">One bearish user (with apparent sarcasm) posted, “$DJT strong support at $0,” while another claimed to have profited $82,000 by shorting the stock.<stembedurl>https://stocktwits.com/theta4life/message/584409755</stembedurl>Additionally, a lock-up period barring former President Donald Trump from selling his shares in the company is nearing its end.&nbsp;According to <a href="https://qz.com/donald-trump-media-stock-holdings-djt-lockup-selloff-1851629076">Quartz</a>, Trump’s stake in DJT is under a six-month lockup period that could end as soon as Sept. 20 — if the stock remains above $12 for any 20 trading days starting Aug. 22. If shares fall below $12, the earliest Trump could sell would be Sept. 25, regardless of the stock’s value.&nbsp;John Rekenthaler, Vice President of Research at Morningstar, reportedly believes DJT is “extremely overvalued” and sees it as a great cash-out opportunity for Trump, who in theory has “well over $2 billion to realize.”DJT’s slide has also been exacerbated by a $16.4 million net loss in Q2 and a 30% drop in revenue.&nbsp; Shares of the company, which have been extremely volatile due to news events involving Trump, have lost more than 65% of their value since going public via a SPAC merger in March.<stembedurl>https://stocktwits.com/RonSwanson1/message/584401019</stembedurl>Trump is set to debate Vice President Kamala Harris live on Sept. 10 in Philadelphia. With DJT stock near record lows and a potential Trump stock sale on the horizon, analysts like Rekenthaler warn that a political defeat could push the stock “to zero.”Read Next: <a href="https://stocktwits.com/news/markets/equity/anf-stock-falls-after-q2-results/c7w7XRoR2P">Abercrombie &amp; Fitch Stock Sinks As CEO Points To 'Increasingly Uncertain Environment' — Retail Bulls Aren’t Backing Down</a>&nbsp;&nbsp;&nbsp; &nbsp;

Donald Trump speaking with supporters at a campaign rally at the Phoenix Convention Center in Phoenix, Arizona.

Trump Media & Tech Stock Plummets, Retail Gets ‘Extremely Bearish’ After Key Execs Dump Shares 

A six-month lock-up period barring former President Donald Trump from selling his shares in the company is also nearing its end.

Trump Media &amp; Technology Group (DJT), the parent company of Truth Social, saw its shares fall to a new post-merger low of $21.99 on Tuesday, with retail investor sentiment souring on the stock. &nbsp;According to Stocktwits, sentiment for DJT has turned bearish, falling from ‘neutral’ (36/100) a day earlier.<figure class="image"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DJT_sentiment_and_message_volume_Aug_20_14dd9018ba.png" alt="DJT sentiment and message volume Aug 20.png" width="1310" height="316"><figcaption>DJT sentiment and message volume Aug 20</figcaption></figure>The stock hit an intraday low of $22.24 on Monday, slipping nearly 1.3% from its previous low seen in mid-April.This downturn follows several weeks of declining stock prices, exacerbated by a $16.4 million net loss in Q2 and a 30% drop in revenues.Since its Nasdaq debut in March under the ticker DJT, following a merger with Digital World Acquisition Corp., Trump Media's stock has plunged over 61%, with a nearly 36% drop in the past month alone.Shares of the company have been on a volatile ride this year, primarily driven by <a href="https://stocktwits.com/news/markets/equity/trump-media-stock-retail-sentiment-extremely-bearish-after-biden-exits-2024-race/c7rTFviRv">news events</a> involving former President Donald Trump, the company's majority shareholder.Recent setbacks include the stock slipping after Trump returned to Twitter (now X) for a conversation with Elon Musk, the fallout from Trump’s legal troubles and debate performance against President Joe Biden.There was some limited upside movement following <a href="https://stocktwits.com/news/markets/equity/Trump-stocks-surge-after-shooting-but-retail-traders-divided/c7AZ9lnRT">the assassination attempt</a> on Trump in July during a rally near Butler, Pennsylvania.The stock is facing more pressure as the Democratic National Convention convenes in Chicago on Thursday, when Vice President Kamala Harris will formally accept her nomination for the White House race.<stembedurl>https://stocktwits.com/RickeyBobby/message/583493412</stembedurl>Despite Trump Media's rollout of its live TV streaming service, Truth+, retail investors remain pessimistic, with some asking the hard questions.&nbsp;<stembedurl>https://stocktwits.com/Mishka1/message/583489536</stembedurl>As the political landscape heats up, DJT’s stock stands on increasingly shaky ground.See Also:&nbsp;<a href="https://stocktwits.com/news/markets/equity/govx-tnpx-ebs-siga-stocks-face-mixed-signals-on-mpox-news/c7voqTBRTH">Emergent, Geovax, Tonix, Siga: Which Mpox-Linked Stocks Are Retail Investors Most Excited About?</a>

Despite Trump Media's rollout of its live TV streaming service, Truth+, retail investors remain pessimistic. Photo via Rawpixel

Trump Media Stock Declines To Record Post-Merger Low, Retail Sentiment Sours

The stock, closely tied to former President Trump’s actions and legal issues, has plunged over 61% since going public via a SPAC merger this year.

BlackRock Institutional Trust Company N.A. - iShares Morningstar Small-Cap ETF

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

ISCB
iShares Morningstar Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ISCB News

ISCBiShares Morningstar Small-Cap ETF